ASH 2025 | EndRAD trial: high EFS & OS after non-TBI conditioning and allogeneic HCT in NGS MRD-negative B-ALL
Hisham Abdel-Azim
• 6 Dec 2025
In this press briefing, Hisham Abdel-Azim, MD, MS, Loma Linda University School of Medicine, Loma Linda, CA, presents findings from the Phase II EndRAD trial (NCT03509961), which demonstrated high event-free survival (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation sequencing measurable residual disease (NGS-MRD) negative B-cell acute lymphoblastic leukemia (B-ALL). This press briefing took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
